1.Pleomorphic Carcinoma of the Lung with High Serum Beta-human Chorionic Gonadotropin Level and Gynecomastia.
Kerem OKUTUR ; Baris HASBAL ; Kubra AYDIN ; Mustafa BOZKURT ; Esat NAMAL ; Buge OZ ; Kamil KAYNAK ; Gokhan DEMIR
Journal of Korean Medical Science 2010;25(12):1805-1808
Although gynecomastia is a well-defined paraneoplastic syndrome in patients with non-small cell lung cancer, the association with pleomorphic carcinoma has not been reported. A 50-yr-old man presented with bilateral gynecomastia and elevated serum beta-human chorionic gonadotropin (beta hCG) level. Chest tomography showed a mass in the right middle lobe. Right middle lobectomy and mediastinal lymph node dissection were performed. beta hCG levels decreased rapidly after surgery. Histological examination revealed pleomorphic carcinoma with positive immunostaining for beta hCG. Serum beta hCG levels began to increase gradually on postoperatively 4th month. Computed tomography detected recurrence and chemotherapy was started. After second cycle of chemotherapy, beta hCG levels decreased dramatically again and tomography showed regression in mass. Patient died 6 months later due to brain metastasis. beta hCG expression may be associated with aggressive clinical course and increased risk of recurrence, also beta hCG levels may be used to evaluate therapy response in patients with pleomorphic carcinoma.
Brain Neoplasms/radiotherapy/secondary
;
Carcinoma, Non-Small-Cell Lung/complications/*diagnosis/pathology
;
Chorionic Gonadotropin, beta Subunit, Human/*blood
;
Gynecomastia/*etiology
;
Humans
;
Lung Neoplasms/complications/*diagnosis/pathology
;
Lymph Nodes/surgery
;
Male
;
Middle Aged
;
Recurrence
;
Risk Factors
;
Tomography, X-Ray Computed
2.Prognostic Significance of Initial Platelet Counts and Fibrinogen Level in Advanced Non-Small Cell Lung Cancer.
Kyung Hee KIM ; Tae Yun PARK ; Ji Yeun LEE ; Sang Min LEE ; Jae Joon YIM ; Chul Gyu YOO ; Young Whan KIM ; Sung Koo HAN ; Seok Chul YANG
Journal of Korean Medical Science 2014;29(4):507-511
Thrombocytosis and coagulation systems activation are commonly associated with disease progression and are suggested poor prognostic factors in patients with malignancies. This study aimed to investigate the prevalence and prognostic significance of thrombocytosis and elevated fibrinogen levels in patients with advanced non-small cell lung cancer (NSCLC). Initial platelet counts and fibrinogen levels were reviewed in 854 patients with histologically proven NSCLC. Thrombocytosis was defined as platelet counts > 450 x 10(9)/L. A serum fibrinogen level > 4.5 g/L was considered high. At the time of diagnosis, initial platelet counts and serum fibrinogen levels were evaluated before treatment. Clinicopathologic data including histological type, tumor, node, metastasis (TNM) stage, performance status, treatment method, and survival time were evaluated. Initial thrombocytosis was found in 6.9% of patients, and elevated fibrinogen levels were found in 55.1% of patients. Patients with thrombocytosis had a significantly poorer prognosis than patients with normal platelet counts (P < 0.001). In multivariate survival analysis, thrombocytosis was an independent prognostic factor (P < 0.001). An elevated serum fibrinogen level was associated with poor prognosis (P < 0.001). In conclusion, initial thrombocytosis and a high fibrinogen level are independent factors for predicting poor prognosis in patients with advanced NSCLC.
Aged
;
Blood Platelets/*cytology
;
Carcinoma, Non-Small-Cell Lung/*diagnosis/mortality/pathology
;
Female
;
Fibrinogen/*analysis
;
Humans
;
Lung Neoplasms/*diagnosis/mortality/pathology
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Platelet Count
;
Prognosis
;
Retrospective Studies
;
Survival Rate
;
Thrombocytosis/complications/diagnosis